Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LOGC

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

LogicBio Therapeutics logo

About LogicBio Therapeutics Stock (NASDAQ:LOGC)

Advanced Chart

Key Stats

Today's Range
$7.15
$7.35
50-Day Range
$2.04
$2.07
52-Week Range
$0.26
$3.77
Volume
73,796 shs
Average Volume
168,718 shs
Market Capitalization
$191.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LogicBio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

LOGC MarketRank™: 

LogicBio Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 174th out of 210 stocks in the retail/wholesale sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for LogicBio Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LogicBio Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LogicBio Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LogicBio Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.44% of the float of LogicBio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently decreased by 30.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    LogicBio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LogicBio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.44% of the float of LogicBio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently decreased by 30.98%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 10 people have searched for LOGC on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of LogicBio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LogicBio Therapeutics' insider trading history.
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Stock News Headlines

Trump’s New Order Could Boost Social Security Benefits by 400%
If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier.
See More Headlines

LOGC Stock Analysis - Frequently Asked Questions

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) released its quarterly earnings results on Friday, May, 9th. The company reported ($0.27) earnings per share (EPS) for the quarter. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 81.98% and a negative net margin of 141.03%.
Read the conference call transcript
.

LogicBio Therapeutics (LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB).

Company Calendar

Last Earnings
5/09/2025
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Catalog & mail - order houses
Sub-Industry
N/A
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$317 million
Net Margins
-141.03%
Pretax Margin
-141.67%

Debt

Sales & Book Value

Annual Sales
$287 million
Price / Cash Flow
N/A
Book Value
$8.96 per share
Price / Book
0.81

Miscellaneous

Free Float
24,156,000
Market Cap
$191.84 million
Optionable
Optionable
Beta
2.06
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:LOGC) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners